Recent 8-K filings for FEMY
Highest-materiality recent filing
Femasys gets FDA IDE approval for FemBloc final trial phase, secures $12M financing
- FDA IDE approval to continue enrollment in Part B of FINALE pivotal trial for FemBloc non-surgical permanent birth control.
- $12M senior secured convertible notes issued with potential total proceeds of $58M if all warrants exercised.
-
Femasys appoints John Canning as COO; base $450K, inducement option 150K shares
John Canning appointed COO effective March 30, 2026; annual base salary $450,000 with 40% target bonus.
-
Femasys reports 2025 revenue up 40.8% to $2.3M; net loss $18.6M; cash into Q3 2026
Revenue increased 40.8% to $2,293,313 in 2025 from $1,629,108 in 2024, driven by FemBloc sales.
-
Omnibus Amendment removes Share Combination Event Adjustment from $10.5M+ senior secured convertible notes and warrants, effective Dec 31, 2025.
-
Femasys granted 180-day extension to cure Nasdaq minimum bid price deficiency
Received Nasdaq deficiency notice July 16, 2025; bid price below $1.00 for 30 consecutive days.
-
Femasys files prospectus for ATM offering of up to $9.8M common stock
Prospectus supplement filed Dec 23, 2025 for sale of up to $9.8M in common stock under existing equity distribution agreement.
-
Femasys receives FDA 510(k) clearance for next-gen FemVue Controlled device
FDA 510(k) clearance for FemVue Controlled, integrating FemVue and FemChec technologies.
-
Net loss $4.19M ($0.10/sh) vs $5.41M ($0.24/sh) a year ago on lower R&D spend.
-
Femasys raises $12M via senior secured convertible notes and warrants
Senior secured convertible notes: $12M aggregate principal, 8.5% interest (PIK), conversion price $0.73 (15% premium to close), 10-year maturity.
-
Femasys gets FDA IDE approval for FemBloc final trial phase, secures $12M financing
FDA IDE approval to continue enrollment in Part B of FINALE pivotal trial for FemBloc non-surgical permanent birth control.
-
Femasys updates Nasdaq compliance; pro forma equity ~$5.2M meets $2.5M minimum
Received prior Nasdaq deficiency notice for MVLS below $35M and failure to meet alternative listing standards.
-
Femasys announces $8.0M public offering of common stock and warrants
Underwritten public offering of 10,434,586 shares of common stock, pre-funded warrants for 11,750,000 shares, and common warrants for 22,184,586 shares at combined price $0.36 per unit.
-
Femasys secures UK MHRA approval for FemBloc permanent birth control
MHRA approval validates safety, quality, and effectiveness for UK market.
-
Femasys Q2 2025 sales up 85% to $409K, net loss $4.6M, cash runway into early Q4
Sales $409,268 (+84.8% YoY); net loss $4.59M ($0.16/sh) vs $4.68M ($0.21/sh) prior year.
-
Femasys secures first European order for FemBloc in Spain, approximately $400,000
First commercial European order for FemBloc permanent birth control valued at ~$400,000 USD.
-
Femasys receives Nasdaq minimum bid price non-compliance notice; 180-day cure period
Nasdaq notified Femasys on July 16, 2025, of non-compliance with $1.00 minimum bid price for 30 consecutive business days.
-
Femasys enters $10M equity purchase agreement with Alumni Capital LP
Up to $10M of common stock may be sold to Alumni Capital at Company's election through Dec. 31, 2026.
-
Femasys gets Australian & New Zealand approvals for FemaSeed and FemVue
Regulatory approvals granted for FemaSeed first-line intratubal insemination treatment and FemVue diagnostic.
-
CE mark certification for entire FemBloc System under EU MDR 2017/745; can now be marketed in European Economic Area (27 EU + 3 EFTA states).
-
Femasys raises $4.5M in combined underwritten public offering and concurrent private placement
Underwritten public offering of 3.6M shares at $0.85/share; underwriter granted 30-day option for 540k additional shares.
-
Femasys receives Nasdaq delisting notice for MVLS below $35M; 180-day cure period until Nov 2025
Nasdaq notified Femasys MVLS of common stock was below $35M minimum for 30 consecutive business days.
-
Femasys Q1 sales up 25.9% but net loss widens to $5.9M; cash runway only into early Q3 2025
Sales increased 25.9% YoY to $341K, driven by FemaSeed sales.
-
Femasys reports 52% revenue growth in 2024; net loss widens to $18.8M; cash runway into Q3 2025
Revenue $1.63M, up 52% YoY; net loss $18.8M ($0.85/sh) vs $14.2M ($0.93/sh) in 2023.
-
Femasys gets CE mark for FemBloc delivery system in Europe, polymer approval expected mid-2025
FemBloc delivery system receives first-in-world CE mark certification under EU MDR for non-surgical permanent birth control.
-
Femasys Q3 2024 revenue up 127% to $555K; net loss widens to $5.4M
Revenue $554,908 (+127% YoY); first U.S. and international FemaSeed sales recorded.
-
Femasys Q3 2024 revenue up 127% to $555K; net loss widens to $5.4M
Revenue $554,908 (+127% YoY); first U.S. and international FemaSeed sales in Q3.
-
Femasys secures Spain distribution deals with $1.3M minimum FemaSeed purchase
Partners CMQ (northern Spain) and Durgalab (southern Spain) to distribute FemaSeed and FemVue.
-
Femasys receives FDA 510(k) clearance for FemChec fallopian tube diagnostic
FemChec cleared by FDA for controlled contrast delivery to check tubal status.
-
Femasys receives CE Mark for four women's health products, enters EU market
Received EU MDR certificate and CE Mark for FemaSeed, FemVue, FemCerv, FemCath.
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.85 · Median 0.60 · Most common event other_material